AffaMed Therapeutics’ Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule, has been cleared by the US Food and Drug Administration (FDA). AM712 has been designed to treat retinal vascular diseases and primarily works to block vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), two important pathways associated with retinal diseases. Retinal vascular disease encompasses a range of diseases that affect the blood vessels in the eye and more common types include diabetic retinopathy, hypertensive retinopathy retinal vein occlusion (RVO), and central retinal artery occlusion (CRAO). In January of 2022, a clinical trial application (CTA) for AM712 was approved the CFDA in China. Now, with the US FDA-cleared IND, AM712 can undergo a Phase 1 study to investigate subjects with neovascular age-related macular degeneration (AMD). AffaMed Therapeutics is a biotech company that develops pharmaceutical, digital, and surgical products to address unmet medical needs in ophthalmic, neurological, and psychiatric disorders.
Read more here.
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.